MBIO
Closed
Mustang Bio Inc
2.05
+1.09 (+114.12%)
Last Update: 01 Jul 2025 23:26:00
Yesterday: 0.9551
Day's Range: 0.8926 - 2.13
Send
sign up or login to leave a comment!
When Written:
3.36
Mustang Bio Inc is a clinical-stage biopharmaceutical company that focuses on developing and commercializing novel gene therapies and CAR T cell therapies for the treatment of cancer and rare genetic diseases. The company was founded in 2015 and is headquartered in Worcester, Massachusetts.
Mustang Bio's pipeline includes several gene therapies and CAR T cell therapies that target various types of cancer, including acute myeloid leukemia, solid tumors, and lymphomas. The company's lead product candidate is MB-107, a gene therapy for the treatment of X-linked severe combined immunodeficiency (XSCID), also known as "bubble boy disease." Mustang Bio is also developing MB-106, a CAR T cell therapy for the treatment of B-cell non-Hodgkin's lymphoma.
The company has partnerships with several academic institutions and biopharmaceutical companies, including City of Hope, Nationwide Children's Hospital, and St. Jude Children's Research Hospital. Mustang Bio has also received funding from the National Institutes of Health and the California Institute for Regenerative Medicine.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Mustang Bio's pipeline includes several gene therapies and CAR T cell therapies that target various types of cancer, including acute myeloid leukemia, solid tumors, and lymphomas. The company's lead product candidate is MB-107, a gene therapy for the treatment of X-linked severe combined immunodeficiency (XSCID), also known as "bubble boy disease." Mustang Bio is also developing MB-106, a CAR T cell therapy for the treatment of B-cell non-Hodgkin's lymphoma.
The company has partnerships with several academic institutions and biopharmaceutical companies, including City of Hope, Nationwide Children's Hospital, and St. Jude Children's Research Hospital. Mustang Bio has also received funding from the National Institutes of Health and the California Institute for Regenerative Medicine.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








